BioMarin Pharmaceuticals Inc
Market cap $12.5B
$64.73
BMRN
$64.73
+0.43% today
Buy with €1M virtual cash · No real money
BioMarin Pharmaceuticals Inc (BMRN) is a publicly traded company listed on the XNAS. As of September 16, 2026, Invest's signal rates BMRN a Buy, with the stock up 22% over the past year. You can practice trading BMRN risk-free with €1,000,000 in virtual cash.
Key stats
As of September 16, 2026
Market Cap
$12.5B
Volume
2.3M
52-wk High
$70.98
52-wk Low
$49.26
Day High
$65.67
Day Low
$64.34
P/E (TTM)
174.95
Revenue (TTM)
$3.4B
EPS (TTM)
$0.37
Performance
1M
-2.9%
6M
+15.5%
1Y
+21.8%
Invest signal · BMRN
BuyAlgorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.
BMRN overview
AI overviewRevenue & EPS — last 8 quarters
QoQ rev +29.2%Revenue
$990MEPS (diluted)
$0.23 per shareLatest BMRN news
BioMarin Stops Voxzogo Development for Noonan Syndrome
Zacks Investment Research · 7h ago
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
Zacks Investment Research · Sep 3
Fabry Disease Treatment Market 2026-2031 - Growth Driven by Increasing Adoption of Enzyme Replacement Therapy
GlobeNewswire Inc. · Aug 25
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
GlobeNewswire Inc. · May 26
BioMarin Reveals Dwarfism Study Data, Stock Soars
Benzinga · May 21
About BioMarin Pharmaceuticals Inc
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis.
BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Employees
3,221
30-Day Win Rate · BMRN
10 days
14 days
Last 24 sessions
How to practice trading BMRN
- 1
Use the BMRN buy panel above
Set a quantity and hit Buy at the real market price — right here, nothing to download.
- 2
Trade with €1,000,000 virtual cash
You get a million in virtual money instantly to invest, risk-free.
- 3
Create a free account to save it
Sign up in seconds to keep your portfolio and track its performance.
- 4
Track and compete
Watch your portfolio grow and climb the global leaderboard — or start a private league.
- 5
Prefer mobile? Get the iOS app
Invest is also free on the App Store, synced with your web account.
Top BMRN traders on Invest
Full leaderboardFrequently asked questions
Is BMRN a good stock to buy right now?
As of September 16, 2026, Invest's signal rates BMRN a Buy, based on its price trend, valuation, and fundamentals (P/E around 174.9), with the stock up 22% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading BMRN risk-free first.
What is BioMarin Pharmaceuticals Inc's (BMRN) market cap?
BioMarin Pharmaceuticals Inc has a market capitalization of approximately $12.5B, on trailing-twelve-month revenue of about $3.4B.
How has BMRN stock performed?
BMRN is up 22% over the past year and up 15% over six months. Its 52-week range runs roughly from $49.26 to $70.98. Past performance doesn't predict future results.
How can I practice trading BMRN for free?
On Invest you get €1,000,000 in virtual cash and can buy BMRN at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.
More stocks to practice
Designs the iPhone, Mac, and a huge services ecosystem.
Windows, Office, Azure cloud, and enterprise software.
The leading designer of AI and gaming GPUs.
E-commerce giant and the largest cloud provider (AWS).
Google Search, YouTube, Android, and cloud.
Facebook, Instagram, WhatsApp, and the metaverse.